Embryonic Stem Cell Report
A preliminary report on a prospective clinical study of subretinal transplantation of human embryonic stem cells for dry age-related macular degeneration (AMD) finds a slight improvement in vision (21 letters to 28) during the first 4 months. There were no signs of adverse events or rejection. A future goal is to treat patients earlier in the disease process.
If you found this article interesting, you can get updates in your email inbox any time similar articles are posted. The subscription options you will be presented with are based on your interest in this article. Just click here to sign up for a free membership and get started!